Seres Therapeutics (MCRB) Payables (2014 - 2026)

Seres Therapeutics has disclosed Payables across 13 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Payables fell 46.09% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (down 46.09% YoY), while the FY2025 annual figure was $1.7 million, down 58.76% from the prior year.
• Payables came in at $1.2 million for Q2 2026 at Seres Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $17.9 million in Q4 2022 to a low of $1.2 million in Q2 2026.
• Average Payables over 5 years is $6.7 million, with a median of $5.0 million recorded in 2024.
• Year-over-year, Payables soared 81.08% in 2023 and sank 79.68% in 2025.
• Over 5 years, Payables stood at $17.9 million in 2022, then plunged by 79.65% to $3.6 million in 2023, then climbed by 12.03% to $4.1 million in 2024, then sank by 58.76% to $1.7 million in 2025, then declined by 29.49% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.2 million in Q2 2026, $2.3 million in Q1 2026, and $1.7 million in Q4 2025.